Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.33 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.33 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14952237 | 0.90 | — | — | |
| SCHEMBL14037462 | 0.89 | LGALS8 (0.32) | LGALS8LGALS3LGALS4 | |
| SCHEMBL19143464 | 0.89 | LGALS8 (0.32) | LGALS8LGALS3LGALS4 | |
| SCHEMBL23417369 | 0.86 | MAPK1 (0.42) | LGALS8LGALS3LGALS4SLC2A1 | |
| SCHEMBL22605122 | 0.86 | MAPK1 (0.42) | LGALS8LGALS3LGALS4SLC2A1 | |
| SCHEMBL22605123 | 0.86 | MAPK1 (0.42) | LGALS8LGALS3LGALS4SLC2A1 | |
| SCHEMBL25910742 | 0.86 | MAPK1 (0.42) | LGALS8LGALS3LGALS4SLC2A1 | |
| SCHEMBL26284484 | 0.86 | MAPK1 (0.42) | LGALS8LGALS3LGALS4SLC2A1 | |
| SCHEMBL16729887 | 0.85 | LGALS8 (0.30) | LGALS8 | |
| SCHEMBL18390208 | 0.85 | LGALS8 (0.30) | LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220143064-A1 | TAU ANTISENSE OLIGOMERS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2022-05-12 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-20190136227-A1 | METHOD FOR THE SYNTHESIS OF A BIFUNCTIONAL COMPLEX | NUEVOLUTION AS (DK) | 2019-05-09 | — | — | US | disclosed |
| US-20170335323-A1 | Chiral Library Screen | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143064-A1 | TAU ANTISENSE OLIGOMERS AND USES THEREOF | MAPT, FUS, TARDBP | LGALS8 2983/4885LGALS3 3595/4885LGALS4 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.